BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,727,947 | -20.5% | 1,091,518 | -20.9% | 0.00% | 0.0% |
| Q2 2023 | $9,719,832 | -68.2% | 1,380,658 | -62.3% | 0.00% | -66.7% |
| Q1 2023 | $30,518,836 | +169.4% | 3,659,333 | +270.8% | 0.00% | +200.0% |
| Q4 2022 | $11,328,429 | +5.2% | 986,797 | +15.4% | 0.00% | 0.0% |
| Q3 2022 | $10,770,000 | +33.5% | 854,881 | +12.1% | 0.00% | 0.0% |
| Q2 2022 | $8,066,000 | -37.7% | 762,435 | -4.3% | 0.00% | 0.0% |
| Q1 2022 | $12,950,000 | +162.1% | 796,441 | +123.3% | 0.00% | – |
| Q4 2021 | $4,940,000 | -45.1% | 356,684 | -43.0% | 0.00% | -100.0% |
| Q3 2021 | $8,990,000 | -46.9% | 625,644 | -41.5% | 0.00% | -50.0% |
| Q2 2021 | $16,917,000 | +23.3% | 1,070,128 | -20.7% | 0.00% | 0.0% |
| Q1 2021 | $13,721,000 | +153.8% | 1,349,133 | +85.9% | 0.00% | +100.0% |
| Q4 2020 | $5,407,000 | +83.2% | 725,859 | -15.5% | 0.00% | – |
| Q3 2020 | $2,952,000 | -65.4% | 859,499 | -52.0% | 0.00% | -100.0% |
| Q2 2020 | $8,537,000 | +544.8% | 1,791,548 | +170.8% | 0.00% | – |
| Q1 2020 | $1,324,000 | +1.9% | 661,552 | +75.7% | 0.00% | – |
| Q4 2019 | $1,299,000 | +351.0% | 376,501 | +273.7% | 0.00% | – |
| Q3 2019 | $288,000 | -82.0% | 100,748 | -76.1% | 0.00% | – |
| Q2 2019 | $1,599,000 | -18.6% | 421,933 | +74.8% | 0.00% | – |
| Q1 2019 | $1,965,000 | +466.3% | 241,372 | +461.4% | 0.00% | – |
| Q4 2018 | $347,000 | +39.9% | 42,997 | +32.5% | 0.00% | – |
| Q3 2018 | $248,000 | -62.8% | 32,451 | -72.1% | 0.00% | – |
| Q2 2018 | $666,000 | +157.1% | 116,231 | +114.2% | 0.00% | – |
| Q1 2018 | $259,000 | -10.4% | 54,271 | -7.9% | 0.00% | – |
| Q4 2017 | $289,000 | +109.4% | 58,942 | +124.3% | 0.00% | – |
| Q3 2017 | $138,000 | +55.1% | 26,274 | +63.9% | 0.00% | – |
| Q2 2017 | $89,000 | -57.6% | 16,034 | -35.9% | 0.00% | – |
| Q1 2017 | $210,000 | +89.2% | 25,029 | +43.3% | 0.00% | – |
| Q4 2016 | $111,000 | +164.3% | 17,461 | +80.9% | 0.00% | – |
| Q3 2016 | $42,000 | -6.7% | 9,651 | -39.5% | 0.00% | – |
| Q2 2016 | $45,000 | +181.2% | 15,945 | +189.9% | 0.00% | – |
| Q1 2016 | $16,000 | -93.1% | 5,500 | -75.5% | 0.00% | – |
| Q4 2015 | $232,000 | -64.7% | 22,485 | -61.0% | 0.00% | – |
| Q3 2015 | $657,000 | -82.3% | 57,592 | -76.9% | 0.00% | -100.0% |
| Q2 2015 | $3,716,000 | +729.5% | 248,874 | +400.8% | 0.00% | – |
| Q1 2015 | $448,000 | -24.7% | 49,691 | +1.7% | 0.00% | – |
| Q4 2014 | $595,000 | +114.8% | 48,868 | +72.7% | 0.00% | – |
| Q3 2014 | $277,000 | -76.7% | 28,299 | -69.6% | 0.00% | – |
| Q2 2014 | $1,188,000 | +33.2% | 93,179 | +10.5% | 0.00% | – |
| Q1 2014 | $892,000 | +22.9% | 84,300 | -11.7% | 0.00% | – |
| Q4 2013 | $726,000 | +18.2% | 95,516 | +13.2% | 0.00% | – |
| Q3 2013 | $614,000 | +118.5% | 84,345 | -53.5% | 0.00% | – |
| Q2 2013 | $281,000 | – | 181,245 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |